Mineralys Therapeutics Inc MLYS

$15.33 -0.17 (-1.10%)

Valuation

Market cap
1,372,634,000
Revenue TTM
$0
Net income TTM
$-154,650,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.15

Trading

Volume
1,308,400
Avg volume
1,694,678
Day's range
$14.78 – $15.49
Shares out
88,557,000
Stochastic %K
19%
Beta
0.83
Analysts
Strong Buy
Price target
$44.00

Price

Company profile

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep a...

Show more

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Industry
Biotechnology
Sector
Healthcare
Phone
888 378 6240
Website
https://mineralystx.com
Address
150 N. Radnor Chester Road, Suite F200, Radnor, United States

Latest news